CANTATA EvaluatorSM for CELL

Methodology  
© 2023 BreakoutWatch.com
New CE: Go  
Company Information
Symbol: CELL
Company: PhenomeX Inc.
Company Description: PhenomeX Inc. operates as a functional cell biology company. The company enables scientists to reveal insights on cell function and obtain behavior of each cell. Its suite of tools and services offer unparalleled resolution and speed, accelerating the insights for advancing discoveries that can profoundly improve the prevention and treatment of disease. The company's platforms are used by researchers worldwide, including pharmaceutical companies and comprehensive cancer centers. PhenomeX Inc. is headquartered in Emeryville, California.
Stock is Optionable: Yes
SEC Filings Edgar Online
General Due Diligence and Earnings Date Info: Due Diligence
Exchange: NASDAQ
CANTATA Evaluation for 06/08/2023
CE Zone
(Methodology)
 Time- liness CET CEF CE* Industry Industry
Rank 		Industry
Score
3-2 0/2 4.3 / 7 3.46 / 11 7.76 /18 Biotechnology 81 / 215 79 / 100
*Excluding Timeliness points
Timeliness
Item Data Points Maximum
Possible
1
Currently listed on CwH, DB, HTF or SQZ watchlists
0 1
2
Broke out in last 5 days and within 5% of BoP
0 1
 
Total Timeliness Points
 0 2
CANTATA Evaluation Technical (CET)
Item Data Points Maximum
Possible
1 Price relative to 50 and 200 day moving averages; 50 day relative to 200 day moving average
Last Close: $ 0.5224
50 dma $ 0.00
200 dma $ 0.00
2.24 3
2 Relative Strength Rank
RS 52
1.56 3
3 Rank in Industry
Rank in Industry 321
# of stocks in Industry 601
0.48 1
4 Price relative to 52 week high
% off 52 week high 58.87 %
0.03 1
5 Up/Down Ratio
Up/Down Ratio: 0.0
0.00 1
  Miscellaneous Technical Data (no points assigned)
Beta -9999999999.990
PE (vs. S&P 500) -9999999999.990 (-496770988.57 x)
5yr PE low - high -9999999999.990 - 0
n/a n/a
  Total Technical Points (CET) 4.30 9
CANTATA Evaluation Fundamentals (CEF)
1 Quarter over Quarter Earnings Growth
03/31/23 -0.309 vs. -0.317 [ 2.52 %]
12/31/22 -0.410 vs. -0.263 [ -55.89 %]
09/30/22 -0.315 vs. -0.304 [ -3.62 %]
06/30/22 -0.379 vs. -0.272 [ -39.34 %]
0.08 1
2 Positive Quarterly Earnings 0.60 1
3 Quarterly Earnings Growth Acceleration 0.70 1
4 Year over Year Earnings Growth Rates
12/31/22 -1.424 [ -32 %]    
12/31/21 -1.075 [ -60 %]    
12/31/20 -0.672 [ -93 %]    
12/31/19 -0.349 [ 19 %]    
12/31/18 -0.430 [ 0 %]    
0.08 1
5 Quarter over Quarter Sales Growth Rates
03/31/23 18.500 vs. 20.200 [ -8.42 %]
12/31/22 17.800 vs. 23.200 [ -23.28 %]
09/30/22 21.400 vs. 24.300 [ -11.93 %]
06/30/22 19.200 vs. 19.300 [ -0.52 %]
0.00 1
6 Quarterly Sales Growth Rate Acceleration 0.00 1
7 Forward Earnings Growth Rates
Est. EPS growth current Fiscal Yr to next 43.700 %
Est. EPS Growth Next Fiscal Yr to Following 25.100 %
1.00 1
8 Institutional Ownership
Number of Institutional Owners 171.000
Net shares purchased MRQ ('000) -520.000
Institutional Ownership Details  
0.50 1
9 Return on Equity (ROE)
ROE - TTM -63.25 %
0.00 1
10 Cash Flow:
Cash from operations MRQ -19.600
Earnings TTM -107.12464
Cash from operations TTM -57.000
Cash flow above/below earnings TTM 0.47
0.50 1
11 Net Margins
12/31/22 -124.700%
12/31/21 -84.000%
12/31/20 -67.400%
0.00 1
  Miscelleneous Fundamental Data (no points assigned)
Financial Overview
Long term debt to equity 43.700 %  
Current Fiscal Year End 12/31/23  
Yearly Sales ('000) 12/31/22 78.600
      12/31/21 85.400
      12/31/20 64.300
      12/31/19 56.700
      12/31/18 31.300
n/a n/a
  Total Fundamental Points (CEF) 3.46 11
  Total CANTATA Evaluation Points 7.76 20